Shilpa Viswanathan1, Amy C Justice, G Caleb Alexander, Todd T Brown, Neel R Gandhi, Ian R McNicholl, David Rimland, Maria C Rodriguez-Barradas, Lisa P Jacobson. 1. *Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; †Department of General Medicine, VA Connecticut Healthcare System, West Haven, CT; ‡Division of General Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT; §Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; ‖Department of Epidemiology, Emory University Rollins School of Public Health, Atlanta, GA; ¶Department of Global Health, Emory University Rollins School of Public Health, Atlanta, GA; #Department of Medicine, Emory University School of Medicine, Atlanta, GA; **HIV Medical Affairs, Gilead Sciences, Foster City, CA; ††Atlanta VA Medical Center, Atlanta, GA; ‡‡Infectious Disease Section and Department of Medicine, Michael E. DeBakey VA Medical Center, Houston, TX; and §§Baylor College of Medicine, Houston, TX.
Abstract
BACKGROUND: We examined trends in adherence to highly active antiretroviral therapy (HAART) and HIV RNA suppression and estimated the minimum cutoff of adherence to newer HAART formulations needed for HIV RNA suppression by regimen type. METHODS: We used Veterans Affairs pharmacy dispensing data from the Veterans Aging Cohort Study Virtual Cohort between October 2000 and September 2010 and defined adherence as the duration of time the patient had the medications available, relative to the total number of days between refills for all antiretrovirals in a year. Temporal trends in adherence and viral load suppression were examined by the patient's most frequently used HAART regimen in the year. The minimum needed adherence was defined as the level at which the odds of suppression was not significantly different than that observed with ≥ 95% adherence using repeated-measures logistic regression. RESULTS: A total of 21,865 HAART users contributed 82,217 person-years of follow-up. There was a significant increase (P(trend) < 0.001) in the proportion virally suppressed even among those with <95% adherence (2001: 38% to 2010: 84%), and the trend was similar when restricting to their first HAART regimen. For nonnucleoside reverse transcriptase inhibitor multi-pill users, the odds of suppression did not differ for 85%-89% adherence compared to those with ≥ 95% adherence [odds ratios: 0.82 (0.64-1.04)], but for protease inhibitor users, the odds of suppression significantly differed if adherence levels were <95% compared to ≥ 95% adherence. CONCLUSIONS: Although all HIV-infected persons should be instructed to achieve perfect adherence, concerns of slightly lower adherence should not hinder prescribing new HAART regimens early in HIV infection.
BACKGROUND: We examined trends in adherence to highly active antiretroviral therapy (HAART) and HIV RNA suppression and estimated the minimum cutoff of adherence to newer HAART formulations needed for HIV RNA suppression by regimen type. METHODS: We used Veterans Affairs pharmacy dispensing data from the Veterans Aging Cohort Study Virtual Cohort between October 2000 and September 2010 and defined adherence as the duration of time the patient had the medications available, relative to the total number of days between refills for all antiretrovirals in a year. Temporal trends in adherence and viral load suppression were examined by the patient's most frequently used HAART regimen in the year. The minimum needed adherence was defined as the level at which the odds of suppression was not significantly different than that observed with ≥ 95% adherence using repeated-measures logistic regression. RESULTS: A total of 21,865 HAART users contributed 82,217 person-years of follow-up. There was a significant increase (P(trend) < 0.001) in the proportion virally suppressed even among those with <95% adherence (2001: 38% to 2010: 84%), and the trend was similar when restricting to their first HAART regimen. For nonnucleoside reverse transcriptase inhibitor multi-pill users, the odds of suppression did not differ for 85%-89% adherence compared to those with ≥ 95% adherence [odds ratios: 0.82 (0.64-1.04)], but for protease inhibitor users, the odds of suppression significantly differed if adherence levels were <95% compared to ≥ 95% adherence. CONCLUSIONS: Although all HIV-infectedpersons should be instructed to achieve perfect adherence, concerns of slightly lower adherence should not hinder prescribing new HAART regimens early in HIV infection.
Authors: Niteesh K Choudhry; Michael A Fischer; Jerry Avorn; Joshua N Liberman; Sebastian Schneeweiss; Juliana Pakes; Troyen A Brennan; William H Shrank Journal: Arch Intern Med Date: 2011-05-09
Authors: Amy C Justice; Elizabeth Dombrowski; Joseph Conigliaro; Shawn L Fultz; Deborah Gibson; Tamra Madenwald; Joseph Goulet; Michael Simberkoff; Adeel A Butt; David Rimland; Maria C Rodriguez-Barradas; Cynthia L Gibert; Kris Ann K Oursler; Sheldon Brown; David A Leaf; Matthew B Goetz; Kendall Bryant Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Shawn L Fultz; Melissa Skanderson; Larry A Mole; Neel Gandhi; Kendall Bryant; Stephen Crystal; Amy C Justice Journal: Med Care Date: 2006-08 Impact factor: 2.983
Authors: Keri N Althoff; Kate Buchacz; H Irene Hall; Jinbing Zhang; David B Hanna; Peter Rebeiro; Stephen J Gange; Richard D Moore; Mari M Kitahata; Kelly A Gebo; Jeffrey Martin; Amy C Justice; Michael A Horberg; Robert S Hogg; Timothy R Sterling; Angela Cescon; Marina B Klein; Jennifer E Thorne; Heidi M Crane; Michael J Mugavero; Sonia Napravnik; Gregory D Kirk; Lisa P Jacobson; John T Brooks Journal: Ann Intern Med Date: 2012-09-04 Impact factor: 25.391
Authors: Linda Beer; Heather Bradley; Christine L Mattson; Christopher H Johnson; Brooke Hoots; Roy L Shouse Journal: J Acquir Immune Defic Syndr Date: 2016-12-01 Impact factor: 3.731
Authors: Tracey E Wilson; Emma Sophia Kay; Bulent Turan; Mallory O Johnson; Mirjam-Colette Kempf; Janet M Turan; Mardge H Cohen; Adaora A Adimora; Margaret Pereyra; Elizabeth T Golub; Lakshmi Goparaju; Lynn Murchison; Gina M Wingood; Lisa R Metsch Journal: Am J Prev Med Date: 2018-04-12 Impact factor: 5.043
Authors: Kathy K Byrd; John G Hou; Ron Hazen; Heather Kirkham; Sumihiro Suzuki; Patrick G Clay; Tim Bush; Nasima M Camp; Paul J Weidle; Ambrose Delpino Journal: J Acquir Immune Defic Syndr Date: 2019-11-01 Impact factor: 3.731
Authors: Jose R Castillo-Mancilla; Todd T Brown; Kristine M Erlandson; Frank J Palella; Edward M Gardner; Bernard J C Macatangay; Elizabeth C Breen; Lisa P Jacobson; Peter L Anderson; Nikolas I Wada Journal: Clin Infect Dis Date: 2016-09-22 Impact factor: 9.079
Authors: Lesley S Park; Janet P Tate; Keith Sigel; David Rimland; Kristina Crothers; Cynthia Gibert; Maria C Rodriguez-Barradas; Matthew Bidwell Goetz; Roger J Bedimo; Sheldon T Brown; Amy C Justice; Robert Dubrow Journal: AIDS Date: 2016-07-17 Impact factor: 4.177